PARCA (a digital tool) to improve Justice and Health

项目摘要/摘要 在美国，近440万人接受社区监督，其中大多数(约 80%)在试用期内接受监督1.司法涉案人员(JIP)的寿命增加474% 在过去的12个月里，奥施康定的使用增加了303%，在过去的12个月中，使用增加了256% 与普通人群相比，最近12个月服用了止痛药。3解决 物质使用和成瘾使个人参与治疗过程，如开始和保留 在这一人群中，药物使用治疗的比率非常低。Q2i成功开发了 缓刑/假释和重入教练申请(PARCA)技术，其中包括一个司法团队(JT) 仪表板连接到专为JIP设计的移动应用程序。该平台使JIP能够设置和管理其 同时帮助他们解决健康的社会决定因素(SDOH)，以便 促进和补充物质使用治疗过程。它提供了分步指南，并列出了 为实现这些目标，日本政府间合作伙伴可以联系的本地服务和资源。同时，它也给了我们 JT是一个仪表盘，可以更深入地了解JIP是如何管理他们的计划的。这一增加的连接 JT和JIP之间的沟通旨在改善社区监督流程。在……里面 此阶段1/阶段2 Fast Track STTR应用，Q2i的PARCA平台将在 达拉斯和伊达尔戈县测试其有效性。第一阶段的主要目标是加强PARCA JIP平台。研究小组将通过招聘三组2名PPO/案例经理来实现这一目标 将PARCA与五个在过去12个月内使用任何阿片类药物的客户(JIP总数=30)一起使用2- 几周。该团队将与PPO及其客户进行访谈，以告知我们以用户为中心的设计 迭代次数。初步访谈将描述成功的社区监督的障碍和挑战 包括获得Moud治疗，以及如何改进PARCA以应对这些挑战。以下为- UP访谈将描述可行性(使用PARCA平台功能)和可接受性(参与 通过用户参与日志使用PARCA平台)使用PARCA平台定位和访问Moud 治疗。第二阶段的总体目标是测试照常监督(SAU)和 PARCA帮助社区监督下的JIP从事药物使用治疗过程并减少 随后参与犯罪行为。使用阶梯式楔形有效性设计，我们将评估 PARCA平台涵盖缓刑/假释官(PPO)(N=60)、缓刑/假释犯(N=600)。PPO将 被随机分成三组，每组20人，使用PARCA。最后，我们将评估可接受性和 监管人员和司法人员(JIP)建立PARCA平台的可行性以及 PARCA改善了主管和JIP之间的工作联盟。

PROJECT SUMMARY/ABSTRACT Nearly 4.4 million individuals are on community supervision in the United States, with the majority (about 80%) being supervised under probation.1 Justice involved persons (JIPs) have a 474% increased lifetime experience with heroin, a 303% increased use of OxyContin in the last 12 months, and a 256% increased use in pain medication in the last 12 months, compared to the general population.3 One important step in addressing substance use and addiction is getting individuals engaged in the treatment process, as initiation and retention rates are very low for substance use treatment among this population. Q2i successfully developed the Probation/Parole And Reentry Coach Application (PARCA) technology, which includes a Justice Team (JT) Dashboard connected to a mobile app designed for JIPs. The platform enables JIPs to set and manage their personal goals while assisting them in addressing the social determinants of health (SDOH) in order to facilitate and supplement the substance use treatment process. It provides a step-by-step guide and identifies local services and resources that the JIPs can connect with to accomplish these goals. At the same time, it gives the JT a dashboard that enables greater insight on how a JIP is managing their plan. This increased connection and communication between the JT and the JIP is designed to improve the community supervision process. In this Phase 1/Phase 2 Fast Track STTR application, Q2i’s PARCA platform will be refined and implemented in Dallas and Hidalgo Counties to test its efficacy. The primary goal of Phase I is to enhance the PARCA platform for JIP. The study team will accomplish this by recruiting three sets of 2 PPOs/Case Managers willing to use PARCA with five of their clients who have used any opioids in the last 12 months (total JIPs = 30) for 2- weeks. The team will conduct interviews with PPOs and their clients that will inform our user-centered design iterations. Initial interviews will describe barriers and challenges to successful community supervision including accessing MOUD treatment and how PARCA can be improved to address these challenges. Follow- up interviews will describe feasibility (use of the PARCA platform features) and acceptability (engagement with PARCA platform through user engagement logs) of using PARCA platform to locate and access MOUD treatment. The overall goal of Phase II is to test the relative efficacy of supervision as usual (SAU) and PARCA in helping JIPs under community supervision engage in substance use treatment process and reduce subsequent involvement in criminal behavior. Using a stepped wedge effectiveness design, we will evaluate the PARCA platform across probation/parole officers (PPOs) (N=60), probationers/parolees (N=600). PPOs will be randomized in three clusters of 20 people to utilize PARCA. Lastly, we will assess the acceptability and feasibility of PARCA platform by supervision officers and justice-involved persons (JIPs) and whether PARCA improves the working alliance between supervisors and JIPs.